Ipilimumab, an anti‐CTLA‐4 inhibitor, has emerged as a promising therapeutic option when combined with anti‐PD‐1/PD‐L1 agents in advanced HCC, as evidenced by recent phase III trials such as CheckMate 9DW and HIMALAYA [16]. This evidence concerns the gene CTLA4 and hepatocellular carcinoma.